Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; and New York-Presbyterian Medical Center, New York, New York.
Ann Am Thorac Soc. 2018 Feb;15(Suppl 1):S57-S60. doi: 10.1513/AnnalsATS.201705-386KV.
The use of extracorporeal membrane oxygenation to support patients with cardiac and respiratory failure has increased substantially in the last decade. Although the evidence base for its use in adults with respiratory failure is growing, many questions remain to be answered. Ongoing research is aimed at clarifying the role of extracorporeal membrane oxygenation, as well as extracorporeal carbon dioxide removal, in various forms of hypoxemic and hypercapnic respiratory failure, and at defining the optimal techniques for its use. This, of course, is a moving target, as advances in the technology of extracorporeal membrane oxygenation, and the potential development of a true artificial lung, continue at a brisk pace.
在过去的十年中,体外膜肺氧合(ECMO)在支持心搏和呼吸衰竭患者方面的应用大大增加。尽管其在成人呼吸衰竭中的应用证据不断增加,但仍有许多问题有待解答。正在进行的研究旨在阐明 ECMO 以及体外二氧化碳去除在各种低氧血症和高碳酸血症呼吸衰竭中的作用,并确定其使用的最佳技术。当然,这是一个不断变化的目标,因为 ECMO 技术的进步以及真正的人工肺的潜在发展都在迅速推进。